Stock Detail
EXELIXIS INC
Biotechnology
EXEL @ Yahoo Finance | EXEL Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $4.16 | $4.35 | $-0.11 | -2.58% | 0.00 | $4.27 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $4.19 | $4.16 | 1.72M | 539.49M | 1.77M | 59.43 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 4.41 | 4.28 | 4.22 | 4.09 | 4.03 |
Stock Profile
Exelixis, Inc. engages in the discovery and development of pharmaceutical products for the treatment of cancer, metabolic disorders, cardiovascular disease, and other serious diseases. Its clinical development pipeline includes various compounds in cancer and renal disease: XL119 (becatecarin), which is in a Phase III clinical trial in patients with inoperable bile duct tumors and which was exclusively licensed to Helsinn Healthcare SA with rights to reacquire commercial rights for North America; XL647, XL999, XL880, and XL820 that are in Phase I clinical trials in cancer; and XL844 and XL184, anticancer compounds for which it filed investigational new drug applications. The company's preclinical pipeline comprises six programs. The preclinical oncology programs consist of development candidates that focus on inhibiting the RAF (XL281), Akt/S6k (XL418), and IGF1R (XL228) kinases that are implicated in various cancers. In preclinical metabolic disease programs, which consist of Liver X Receptor, Farnesoid X Receptor, and Mineralocortiocoid Receptor programs, the company is developing small molecules that modulate nuclear hormone receptors implicated in various metabolic and cardiovascular disorders. Exelixis has alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, and Genentech. The company was founded as Exelixis Pharmaceuticals, Inc. in 1994 and changed its name to Exelixis, Inc. in 2000. Exelixis is headquartered in South San Francisco, California.